KIO-104 / Kiora Pharma - LARVOL DELTA

Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 (Yahoo Finance) - "Key first quarter and 2025 year-to-date corporate highlights include: Received approval to initiate KLARITY, a Phase 2 clinical trial evaluating KIO-104 for the treatment of retinal inflammation; Reported preclinical data on KIO-104 at ARVO 2025, further supporting its potential as a treatment for inflammatory and proliferative retinal diseases; Continued patient enrollment in the ongoing functional endpoint study, work designed to validate functional vision outcomes and serve as an on-ramp study to ABACUS-2; Received $1.8 million in reimbursed Q4 2024 R&D expenses from Théa Open Innovation (Laboratoires Théa) for activities related to KIO-301."

Commercial • New P2 trial • Preclinical • Trial status • Retinal Disorders

Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy (Kiora Pharma Press Release) - "Kiora Pharmaceuticals, Inc...today announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The findings further support KIO-104 as a promising therapeutic candidate for inflammatory and proliferative diseases of the retina that lead to vision threatening scarring. The presentation, titled, 'KIO-104, a novel small molecule inhibitor of DHODH, effectively prevents proliferative vitreoretinopathy in a rabbit model,' was presented by Romana Seda-Zehetner, MSc MScTox, Kiora's Director, Preclinical Development at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting....By disrupting an essential molecular pathway for rapidly dividing cells, de novo biosynthesis of pyrimidine nucleotides, KIO-104 significantly reduced scar formation in a dose-dependent manner."

Preclinical • Retinal Disorders